Sermorelin
Research Overview · Mechanism of Action · Reconstitution Guide
Overview
Sermorelin (GHRH 1-29 NH₂) is a synthetic 29-amino acid peptide corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone. It was the first GHRH analogue approved by the FDA (for pediatric GH deficiency diagnosis) and has been extensively studied as a diagnostic and therapeutic agent for GH axis evaluation. Unlike recombinant HGH, sermorelin stimulates endogenous GH production through the pituitary's natural regulatory mechanisms.
Mechanism of Action
Sermorelin binds GHRH receptors (GHRHR) on anterior pituitary somatotrophs, activating Gs-coupled adenylyl cyclase and elevating cAMP. This stimulates GH gene transcription and pulsatile GH secretion. Because sermorelin acts upstream of the pituitary, GH release remains subject to normal somatostatin feedback, preserving physiological regulation. The short half-life (~10–20 minutes) produces a GH pulse that mirrors natural GHRH-driven secretion.
Key Studies & References
Walker RF (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 1:307–308.
Prakash A & Goa KL (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 12:139–157.
Bacteriostatic Water Reconstitution Guide
Research Use Only — The following reconstitution information is provided for in vitro laboratory research purposes only. Not for human or veterinary use.
Recommended Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Standard Volume
Add 2 mL bacteriostatic water to a 3 mg vial to yield a 1500 mcg/mL solution. For a 9 mg vial, add 9 mL for a 1000 mcg/mL solution.
Working Concentration
1000–1500 mcg/mL standard working concentration.
Storage (Reconstituted)
Reconstituted: 2–8°C, use within 14 days (shorter than many peptides due to relative instability). Lyophilized: -20°C.
Stability Window
Sermorelin is less stable in solution than many peptides — use within 14 days of reconstitution. Minimize freeze-thaw cycles.
Technique
Inject solvent slowly along the vial wall. Swirl gently. Sermorelin dissolves readily.
Notes
Sermorelin's relatively short solution stability (14 days vs. 28 days for more stable peptides) should be factored into research planning. Reconstitute only what will be used within the stability window.
Research Dosing Reference
The following dosing information is derived from published clinical and preclinical research literature and is provided for reference purposes only.
Clinical / Human Research Range
Diagnostic use: 1 mcg/kg IV bolus. Therapeutic studies: 0.2–0.3 mg subcutaneous nightly.
Preclinical Models
Rodent studies: 1–10 mcg/kg subcutaneous or IV.
Calculation Example
For a 1000 mcg/mL solution: a 300 mcg research dose = 0.3 mL (30 units on a 100-unit insulin syringe).